Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.65 |
| ▸ | NPC1 | O15118 | 6/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | MAPT | P10636 | 5/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2532969 | 0.79 | RAB9A (0.72) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6647977 | 0.78 | MTNR1B (0.82) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4122551 | 0.76 | MAPT (0.72) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6427617 | 0.76 | RAB9A (0.62) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL11464590 | 0.76 | ALDH1A1 (0.62) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL8290684 | 0.75 | CISD2 (0.83) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6427480 | 0.75 | MEN1 (0.75) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4105155 | 0.75 | MAPT (1.00) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL11188238 | 0.75 | HPGD (0.68) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6632076 | 0.75 | NPC1 (1.00) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050222408-A1 | Heterocyclic amides with anti-tuberculosis activity | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2005-10-06 | — | — | US | disclosed |
| US-20050026968-A1 | Heterocyclic amides with anti-tuberculosis activity | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222408-A1 | Heterocyclic amides with anti-tuberculosis activity | TST, KAT5, NDUFS5 | RAB9A 2836/4885NPC1 1957/4885ALDH1A1 2116/4885 |
| US-20050026968-A1 | Heterocyclic amides with anti-tuberculosis activity | TST, KAT5, HDAC5 | RAB9A 3116/4885NPC1 1752/4885ALDH1A1 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.